Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda
Preclinical protein degradation play Plexium Inc. raised $35 million in an extension of its series A round and appointed Mike Grey as chairman. The financing, led by Lux Capital and Pivotal BioVentures, brings the A round to $63 million. Existing investors Column Group and DCVC Bio also participated. Grey is a venture partner at Pappas Ventures; executive chairman of Amplyx Pharmaceuticals Inc., Reneo Pharmaceuticals Inc. and Spruce Biosciences Inc. (NASDAQ:SPRB); and chairman of Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) in addition to holding other board seats.
Immunotech gains China rights to renal cancer program
T-Cure Bioscience Inc. granted China rights to Immunotech Biopharm Ltd. (HKEX:6978) for 800TCR, a HERV-E targeting TCR therapy for renal cell cancer (RCC). Immunotech will make an upfront payment and T-Cure is eligible for milestone payments and tiered royalties. Financial terms were not disclosed. The TCR therapy is in a Phase I trial at National Heart Lung and Blood Institute to treat metastatic clear cell RCC that failed an angiogenic inhibitor and a checkpoint inhibitor...